Higher bioavailability of magnesium citrate as compared to magnesium oxide shown by evaluation of urinary excretion and serum levels after single-dose administration in a randomized cross-over study

Table 1 Analysis of renally eliminated magnesium (A_{e 0-24h}) in mmol

Time point	Study product	Mean (SD)	ANOVA
			Adj. mean difference	95% CI	p-value
Stop-of-saturation	Biolectra^a	6.9 (1.23)	0.145	(−0.276, 0.565)	0.4784
Stop-of-saturation	Verla^a	7.0 (1.67)	0.145	(−0.276, 0.565)	0.4784
Profile day	Biolectra	6.7 (1.43)	0.565	(0.212, 0.918)	0.0034*
Profile day	Verla	7.2 (1.48)	0.565	(0.212, 0.918)	0.0034*

Adjusted mean difference, 95% CI and p-value are based on an ANOVA model with study product, sequence, period and subject within sequence as considered effects. Statistical significance at a level of 5% is given if the 95% confidence interval of the adjusted mean difference does not include 0, respectively if the p-value is <0.05. Statistical significance is denoted by an asterisk (*)
CI confidence interval, SD standard deviation; Biolectra Biolectra® Magnesium 300 mg Kapseln; Verla Magnesium Verla® purKaps
^aHere, the name of the study product taken on the following profile day is provided. No study product was given on stop-of-saturation days

ISSN: 2055-0928